"Every detail, from how we cultivate to how we train our team, was designed to meet the highest pharmaceutical standards"

Greek grower Curity Pharma has added another building block to its pharmaceutical strategy with the announcement that the company has received GACP certification for its cultivation site in Larissa. The news follows the operating license the grower secured earlier this year, and marks the first official confirmation that the systems built into the facility since day one are holding up to external scrutiny.

"Securing GACP certification is a milestone that affirms the path we have been on since day one," says Manos Chatiras, President and Chief Executive Officer. "From the very beginning, we built our facility around the strictest GACP and GMP protocols, not as an afterthought, but as a foundation. Every detail, from how we cultivate to how we train our team, was designed to meet the highest pharmaceutical standards. Rather than prompting change, this certification validates the systems we have had in place all along. As we move toward our first commercial batches, it confirms we are ready to deliver clean, consistent, high quality products that can transition smoothly into GMP level processing."

The Larissa site features a GMP compliant hybrid greenhouse that combines the controlled environment of indoor cultivation with the natural advantages of the Greek climate.

With GACP secured, Curity is now preparing for the next regulatory step. "Our focus now is firmly on EU GMP certification," Manos says. "It is the natural next step, and something we have been preparing for since the earliest stages of design. GMP governs how cannabis is processed and turned into finished medical products, so we are finalizing validations and procedures to meet those requirements head on. Once we are certified, we will be able to manufacture and distribute medical cannabis products across Europe and other tightly regulated markets with full compliance and confidence."

© Curity Pharma

Regulatory check marks aside, the company sees the certification as a signal to the international market. "This certification does more than open doors, it sends a message. It shows the international market that Curity is serious about quality andpri deeply committed to pharmaceutical standards. It is a stepping stone that strengthens our export ambitions and positions Greece as a credible, high standard player in medical cannabis. Our aim is simple. When people see Made in Greece, they should think of quality, innovation, and trust. GACP was our foundation. EU GMP will be our launchpad."